CymaBay Therapeutics Inc. (CBAY)
32.48
0.01 (0.03%)
At close: Mar 21, 2024, 8:00 PM
0.03% (1D)
| Bid | n/a |
| Market Cap | 3.73B |
| Revenue (ttm) | 31.07M |
| Net Income (ttm) | -111.68M |
| EPS (ttm) | -0.99 |
| PE Ratio (ttm) | -32.80808080808081 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 8,354,629 |
| Avg. Volume (20D) | 3,944,615 |
| Open | 32.49 |
| Previous Close | 32.47 |
| Day's Range | 32.48 - 32.50 |
| 52-Week Range | 7.26 - 32.50 |
| Beta | 0.32 |
About CBAY
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2014
Employees 101
Stock Exchange NASDAQ
Ticker Symbol CBAY
Website https://www.cymabay.com